Clinical Trials

Esperance Pharmaceuticals, Inc. has completed a multi-center Phase 2 clinical trial testing EP-100 as a treatment for patients with LHRH receptor-expressing ovarian cancer. The goals of the Phase 2 trial are to evaluate EP-100’s safety and potential efficacy

For more information about the trial or how to enroll, please visit ("search for clinical trials", "EP-100 or Esperance") or contact us.